INmune Bio Inc (INMB) Chairman Acquires $109,890.00 in Stock

INmune Bio Inc (NASDAQ:INMB) Chairman Raymond Joseph Tesi bought 11,100 shares of the company’s stock in a transaction dated Thursday, May 2nd. The stock was bought at an average price of $9.90 per share, with a total value of $109,890.00. The purchase was disclosed in a document filed with the SEC, which is available at the SEC website.

Shares of INMB stock traded down $0.21 on Monday, reaching $10.50. 8,220 shares of the company’s stock were exchanged, compared to its average volume of 16,871. INmune Bio Inc has a 52 week low of $7.00 and a 52 week high of $11.25.

Separately, Maxim Group initiated coverage on INmune Bio in a report on Tuesday, March 19th. They issued a “buy” rating and a $13.00 target price for the company.

TRADEMARK VIOLATION NOTICE: This piece of content was first reported by The Lincolnian Online and is the property of of The Lincolnian Online. If you are reading this piece of content on another publication, it was copied illegally and reposted in violation of US and international copyright & trademark law. The original version of this piece of content can be read at https://www.thelincolnianonline.com/2019/05/06/inmune-bio-inc-inmb-chairman-acquires-109890-00-in-stock.html.

About INmune Bio

INmune Bio Inc, a clinical-stage immunotherapy company, focuses on engineering and harnessing the innate immune system to treat the patient's cancer. The company intends to develop and commercialize product candidates to treat diseases comprising hematologic malignancies and solid tumors. Its development programs include INKmune, which focuses on treating women with relapse refractory ovarian carcinoma; and INB03 that treats patients with advanced cancers with elevated biomarkers of inflammation, including elevated levels of myeloid derived suppressor cells in their blood.

Further Reading: How Do I Invest in Dividend Stocks

Receive News & Ratings for INmune Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for INmune Bio and related companies with MarketBeat.com's FREE daily email newsletter.